EVH
Evolent Health Inc
Evolent Health Inc historical holders
total: 2
Durable Capital Partners Evolent Health Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2025 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q3
Henry Ellenbogen has been an institutional investor in Evolent Health Inc (EVH) since 2025 Q2. According to 2026 Q1 report, Henry Ellenbogen doesn't hold any shares. The fund/company first acquired EVH in 2025 Q2, initially purchasing about 6.42M shares. Since the initial investment, Durable Capital Partners has made 1 more transaction in this position.
When did Henry Ellenbogen exit their EVH position?
Henry Ellenbogen no longer holds Evolent Health Inc (EVH). They sold off their entire position in 2025 Q3, closing out an investment that began in 2025 Q2.
When did Henry Ellenbogen first invest in EVH?
Henry Ellenbogen first invested in Evolent Health Inc (EVH) in 2025 Q2 at the reported quarter-end price of $11.26 per share, acquiring 6,423,293 shares in their initial purchase.
What is Henry Ellenbogen's average cost basis for EVH?
Based on historical transaction data, Henry Ellenbogen's estimated cost basis for Evolent Health Inc (EVH) is approximately $11.26 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $11.26
- Weighted AVG sell price:
- $11.26
EVH transactions history by Durable Capital Partners
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$11.26
|
|
-100% (-6,423,293)
|
-0.55%
|
|
2025 Q2
|
0.55%
|
6,423,293
|
$11.26
|
$72,326,279
|
new
|
+0.55%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.